Huang Ya-Na, Huang Ying, Dai Ji-Hong, Yang Fang-Fang
Department of Respiratory Disease, Children's Hospital of Chongqing Medical University, Chongqing, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2012 Sep;14(9):671-4.
To improve the compliance with subcutaneous specific immunotherapy (SCIT) by analyzing the causes of stopping SCIT in asthmatic children.
A telephone follow-up was conducted in the asthmatic children who received SCIT but did not finished the 3-year course of treatment from June 2005 to October 2010, so as to analyze the causes of stopping SCIT.
A total of 616 asthmatic children received SCIT, and 322 (52.2%) of them stopped SCIT.A total of 127 cases (39.4%) of the 322 children received telephone follow-up. In the 127 children, 53 (41.8%) stopped the SCIT for the reason of bad effecacy, 29 (22.8%) for remission of asthma,12 (9.4%) for expensive fees, 10 (7.9%) for complex process of treatment, 10 (7.9%) for adverse reaction, 9 (7.1%) for long distance from the hospital, and 4 (3.1%) for having no time for treatment. And 69 (54.3%) of them stopped SCIT in the first year, 28 (22.1%) in the second year, and 30 (23.6%) in the third year. Currently, 85 cases (66.9%) of the 127 asthmatic children were up to the control level, and the other 42 cases were not. There was significant difference in the control level of asthma berween the group receiving treatment with regular inhaled corticosteroids (ICS) and the group receiving treatment with irregular ICS (P<0.01).
Bad efficacy, remission of asthma, expensive fees, complex process of treatment, and adverse reaction are the main reasons contributing to the stop of SCIT in asthmatic children. To improve the compliance with SCIT, It is important to make the patients and their parents understand the long treatment course and slow effect of SCIT, encourage them to use objective indices for evaluating the state of asthma, and effectively prevent and treat the adverse reactions.
通过分析哮喘儿童皮下特异性免疫治疗（SCIT）停药原因，提高其治疗依从性。
对2005年6月至2010年10月接受SCIT但未完成3年疗程的哮喘儿童进行电话随访，分析其停药原因。
共有616例哮喘儿童接受SCIT，其中322例（52.2%）停药。322例儿童中共有127例（39.4%）接受电话随访。在这127例儿童中，53例（41.8%）因疗效不佳停药，29例（22.8%）因哮喘缓解停药，12例（9.4%）因费用昂贵停药，10例（7.9%）因治疗过程复杂停药，10例（7.9%）因不良反应停药，9例（7.1%）因距医院路途远停药，4例（3.1%）因没时间治疗停药。其中69例（54.3%）在第1年停药，28例（22.1%）在第2年停药，30例（23.6%）在第3年停药。目前，127例哮喘儿童中85例（66.9%）病情达到控制水平，其余42例未达到。规律吸入糖皮质激素（ICS）治疗组与不规律ICS治疗组哮喘控制水平差异有统计学意义（P<0.01）。
疗效不佳、哮喘缓解、费用昂贵、治疗过程复杂及不良反应是哮喘儿童停止SCIT治疗的主要原因。为提高SCIT治疗依从性，使患者及其家长了解SCIT疗程长、起效慢，鼓励其采用客观指标评估哮喘状态，并有效防治不良反应很重要。
